{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T22:59:02Z","timestamp":1780786742938,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007835","name":"Wenzhou Medical University","doi-asserted-by":"publisher","award":["2024R237"],"award-info":[{"award-number":["2024R237"]}],"id":[{"id":"10.13039\/100007835","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018553","name":"Science and Technology Plan Project of Wenzhou Municipality","doi-asserted-by":"publisher","award":["Y20240372"],"award-info":[{"award-number":["Y20240372"]}],"id":[{"id":"10.13039\/501100018553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018553","name":"Science and Technology Plan Project of Wenzhou Municipality","doi-asserted-by":"publisher","award":["Y20240376"],"award-info":[{"award-number":["Y20240376"]}],"id":[{"id":"10.13039\/501100018553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jgar.2025.10.006","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:17:44Z","timestamp":1761128264000},"page":"248-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A reappraisal of carbapenems dosing in febrile neutropenic patients"],"prefix":"10.1016","volume":"45","author":[{"given":"Sun-Ting","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Yu","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Yun","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Han","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Na","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Ben","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.10.006_bib0001","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2147\/IDR.S241263","article-title":"Epidemiology of Febrile neutropenia episodes with gram-negative bacteria infection in patients who have undergone chemotherapy for hematologic malignancies: a retrospective study of 10 years' data from a single center","volume":"13","author":"Zhang","year":"2020","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2025.10.006_bib0002","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jinf.2023.06.023","article-title":"Prolonged vs short-term infusion of \u03b2-lactam antibiotics for the treatment of febrile neutropenia: A systematic review and meta-analysis","volume":"87","author":"Laporte-Amargos","year":"2023","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2025.10.006_bib0003","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","article-title":"Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.jgar.2025.10.006_bib0004","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0924-8579(98)00094-6","article-title":"Carbapenems in clinical practice: a guide to their use in serious infection","volume":"11","author":"Bradley","year":"1999","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.10.006_bib0005","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/14787210.2019.1573670","article-title":"Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation","volume":"17","author":"Schmidt-Hieber","year":"2019","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"10.1016\/j.jgar.2025.10.006_bib0006","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.jgar.2025.10.006_bib0007","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3390\/pharmaceutics12090785","article-title":"Population pharmacokinetics of continuous-infusion meropenem in febrile neutropenic patients with hematologic malignancies: dosing strategies for optimizing empirical treatment against enterobacterales and P. aeruginosa","volume":"12","author":"Cojutti","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jgar.2025.10.006_bib0008","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s13063-020-04323-0","article-title":"Efficacy of extended infusion of \u03b2-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE)","volume":"21","author":"Laporte-Amargos","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.jgar.2025.10.006_bib0009","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/phar.2231","article-title":"Augmented renal clearance","volume":"39","author":"Cook","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2025.10.006_bib0010","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2025.10.006_bib0011","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1586\/14787210.3.1.23","article-title":"Ertapenem: review of a new carbapenem","volume":"3","author":"Zhanel","year":"2005","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"10.1016\/j.jgar.2025.10.006_bib0012","article-title":"Population pharmacokinetics and pharmacodynamics of imipenem in neutropenic adult patients","volume":"53","author":"Lafaurie","year":"2023","journal-title":"Infect Dis Now"},{"key":"10.1016\/j.jgar.2025.10.006_bib0013","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1093\/jac\/dkaa267","article-title":"Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interventional study","volume":"75","author":"Cojutti","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.10.006_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106841","article-title":"Optimal dosing regimen of biapenem based on population pharmacokinetic\/pharmacodynamic modelling and Monte Carlo simulation in patients with febrile neutropenia and haematological malignancies","volume":"62","author":"Rao","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.10.006_bib0015","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-018-0880-z","article-title":"Therapeutic drug monitoring of beta-lactams and other antibiotics in the Intensive care unit: which agents, which patients and which infections?","volume":"78","author":"Muller","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2025.10.006_bib0016","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jgar.2025.10.006_bib0017","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1128\/AAC.40.1.105","article-title":"Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin","volume":"40","author":"Dreetz","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.10.006_bib0018","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.2165\/00003495-200262150-00005","article-title":"Biapenem","volume":"62","author":"Perry","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2025.10.006_bib0019","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ijantimicag.2006.05.033","article-title":"Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea","volume":"28","author":"Lee","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.10.006_bib0020","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10156-011-0271-9","article-title":"Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis","volume":"17","author":"Ohata","year":"2011","journal-title":"J Infect Chemother: [Official J Jpn Soc Chemother"},{"key":"10.1016\/j.jgar.2025.10.006_bib0021","unstructured":"Performance standards for antimicrobial susceptibility testing, M100. 33rd edition Performance standards for antimicrobial susceptibility testing, M100. 33rd edition."},{"key":"10.1016\/j.jgar.2025.10.006_bib0022","unstructured":"EUCAST European Committee on Antimicrobial Susceptibility Testing breakpoint tables for interpretation of MICs and zone diameters; 2024. vVersion 14.0. http:\/\/www.eucast.org."},{"key":"10.1016\/j.jgar.2025.10.006_bib0023","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/jama.2024.9779","article-title":"Continuous vs intermittent \u03b2-lactam antibiotic infusions in critically ill patients with sepsis: the BLING III randomized clinical trial","volume":"332","author":"Dulhunty","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2025.10.006_bib0024","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jgar.2025.10.006_bib0025","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1128\/AAC.31.9.1420","article-title":"Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients","volume":"31","author":"Drusano","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.10.006_bib0026","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1128\/AAC.00891-08","article-title":"Reassessment of recommended imipenem doses in febrile neutropenic patients with haematological malignancies","volume":"53","author":"Lamoth","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.10.006_bib0027","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1345\/aph.1R097","article-title":"Pharmacokinetics and monte carlo simulations of doripenem in patients with febrile neutropenia","volume":"46","author":"Stein","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jgar.2025.10.006_bib0028","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2147\/IDR.S239095","article-title":"A systematic review of Vancomycin dosing in patients with hematologic malignancies or neutropenia","volume":"13","author":"He","year":"2020","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2025.10.006_bib0029","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40262-013-0086-1","article-title":"Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations","volume":"52","author":"Goulenok","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jgar.2025.10.006_bib0030","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/phar.2231","article-title":"Augmented Renal Clearance","volume":"39","author":"Cook","year":"2019","journal-title":"Pharmacotherapy"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525002231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525002231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T22:02:35Z","timestamp":1780783355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525002231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"alternative-id":["S2213716525002231"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.10.006","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A reappraisal of carbapenems dosing in febrile neutropenic patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}